Telix Pharmaceuticals, INSERM and ARRONAX Enter into Translational Research Partnership - Seite 3
About ARRONAX
The Groupement d'Intérêt Public (GIP) ARRONAX is based in Nantes, France. It research infrastructure dedicated to the production of radioactive materials for nuclear medicine, including sterile production for clinical use. The core of the facility is a 70 MeV multi-particle high intensity cyclotron. ARRONAX routinely produces several innovative radionuclides and is one of the few places worldwide producing 211At (astatine). For more information visit www.arronax-nantes.fr
Important Information
This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available.
None of the products described in this release have obtained a marketing authorization from the US Food and Drug Administration.
Lesen Sie auch
Corporate Contact Dr Christian Behrenbruch Telix Pharmaceuticals Limited CEO Email: chris@telixpharma.com Investor and Media Relations Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Telix Pharmaceuticals Limited via Globenewswire